Jefferies Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $150
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Kelly Shi has initiated coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and set a price target of $150 for the company's stock.
December 20, 2023 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies has initiated coverage on Ascendis Pharma with a Buy rating and a price target of $150, which may positively influence the stock's performance in the short term.
Analyst ratings, especially from reputable firms like Jefferies, can significantly impact a stock's performance. A Buy rating combined with a high price target suggests a strong bullish outlook for ASND, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100